Clinical Utility

PromarkerD enables a more comprehensive assessment and informed approach to help:

  • Identify patients at risk of developing DKD within the next four years
  • Implement preventative measures before kidney damage occurs
  • Personalise patient treatment plans
  • Improve patient monitoring and management

 

What can be done?

Early stage chronic kidney disease can be treated through dietary changes, lifestyle modifications and blood pressure controlling drugs, all of which ensure a relatively better quality of life.

  • Janssen’s Invokana® (canagliflozin) – the first FDA approved drug for treating DKD
  • Currently ~20 DKD drugs are at different stages of clinical trials
  • American Diabetes Association (ADA) & the European Association for the Study of Diabetes (EASD) latest guidelines¹ on managing Type 2 Diabetes recommend that patients with cardiovascular disease take a GLP-1 receptor agonist or SGLT2 inhibitor.

 

Early detection can significantly help prevent serious kidney damage

 

1. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia; Diabetes Care https://link.springer.com/article/10.1007/s00125-018-4729-5